河北医科大学学报 ›› 2025, Vol. 46 ›› Issue (6): 626-634.doi: 10.3969/j.issn.1007-3205.2025.06.002

• • 上一篇    下一篇

基于SEER数据库和中国单中心数据对原发性食管小细胞癌患者生存分析的回顾性研究

  

  1. 1.河北医科大学第四医院消化内科,河北 石家庄 050035;2.河北医科大学第四医院病案室,河北 石家庄 050035

  • 出版日期:2025-06-25 发布日期:2025-07-04
  • 作者简介:殷小磊(1985-),男,河北沧州人,河北医科大学第四医院主治医师,医学硕士,从事消化道肿瘤诊治研究。

  • 基金资助:
    河北省省级科技计划资助项目(22377788D)

Aretrospective study on survival analysis of patients with primary esophageal small cell carcinoma based on SEER database and single-center registries in China

  1. 1.Department of Gastroenterology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 
    050035, China; 2.Department of Medical Record Room, the Fourth Hospital of 
    Hebei Medical University, Shijiazhuang 050035, China

  • Online:2025-06-25 Published:2025-07-04

摘要: 目的探讨影响原发性食管小细胞癌(primary small cell carcinoma of the esophagus,PSCCE)患者预后的相关因素,为临床治疗决策提供一定参考。
方法本研究收集了来自监测、流行病学和最终结果(the Surveillance,Epidemiology,and End Results,SEER)数据库和中国单中心登记的数据。纳入2000—2020年诊断为PSCCE的230例患者(SEER队列158例,中国队列72例)。采用Kaplan-Meier分析绘制生存曲线,Log-Rank检验比较生存差异,Cox比例风险回归模型评估预后因素。
结果单因素和多因素Cox回归分析显示,化疗是两队列患者总生存期(overall survival,OS)的独立预后因素。SEER队列多因素分析中,化疗组的HR=0.395(95%CI:0.261~0.597,P<0.001),化疗组中位生存时间(median survival time,MST)为12个月,显著高于非化疗组的3.5个月(P<0.001)。中国队列中,化疗的HR=0.399(95%CI:0.177~0.899,P=0.027),化疗组MST为22.6个月,高于非化疗组9.8个月(P<0.001)。亚组分析显示,化疗对局限期患者同样具有保护作用。SEER队列局限期患者化疗的HR=0.416(95%CI:0.236~0.735,P=0.003),化疗组MST为16个月,高于非化疗组5.5个月(P<0.001);中国队列局限期患者化疗的HR=0.345(95%CI:0.157~0.760,P=0.008),化疗组MST为23.6个月,高于非化疗组9.8个月(P<0.001)。治疗方式比较显示,SEER队列中,放化疗联合手术组MST显著长于单纯化疗组(18个月vs. 10个月,P=0.009);中国队列中,手术联合化疗组MST显著长于单纯手术组(25.8个月vs. 10个月,P<0.001)。
结论化疗是中美PSCCE患者唯一共同的预后影响因素,也是多学科联合治疗里重要的组成部分。针对局限期患者,也应重视化疗的治疗价值,优先选择含化疗的组合方案。


关键词: 食管肿瘤, SEER数据库, 预后

Abstract: Objective To investigate the relevant factors influencing the prognosis of patients with primary small cell carcinoma of the esophagus (PSCCE), providing valuable insights for clinical treatment decision-making. 
Methods This study collected data from the Surveillance, Epidemiology, and End Results (SEER) database and single-center registries in China. A total of 230 PSCCE patients diagnosed between 2000 and 2020 were included (SEER: 158; China: 72). Kaplan-Meier analysis was used to plot survival curves, Log-Rank test was used for survival comparison, and Cox proportional hazards regression was applied to evaluate prognostic factors. 
Results Both univariate and multivariate Cox regression analyses revealed chemotherapy as an independent prognostic factor for overall survival (OS). In the SEER cohort, the hazard ratio (HR) in the chemotherapy group was 0.395 (95%CI: 0.261-0.597, P<0.001), and the median survival time (MST) for the chemotherapy group was 12 months, which was significantly longer than 3.5 months in the non-chemotherapy group (P<0.001). In the Chinese cohort, the HR for chemotherapy was 0.399 (95%CI: 0.177-0.899, P=0.027), with MST of 22.6 months and 9.8 months for the chemotherapy and non-chemotherapy groups respectively (P<0.001). Subgroup analysis demonstrated the protective effect of chemotherapy in limited-stage patients. For the SEER cohort, the HR for chemotherapy in limited-stage patients was 0.416 (95%CI: 0.236-0.735, P=0.003), with MST of 16 months vs. 5.5 months for the chemotherapy and non-chemotherapy groups respectively (P<0.001). For the Chinese 〖JP2〗cohort, the HR for chemotherapy in limited-stage patients was 0.345 (95%CI: 0.157-0.760, P=0.008),〖JP〗 with MST of 23.6 months vs. 9.8 months for the chemotherapy and non-chemotherapy groups respectively (P<0.001). Treatment comparison showed that in the SEER cohort, the MST of the chemoradiotherapy combined with surgery group was significantly longer than that of the chemotherapy-alone group (18 months vs. 10 months, P=0.009). In the Chinese cohort, the MST of the surgery combined with chemotherapy group was significantly longer than that of the surgery-alone group (25.8 months vs. 10 months, P<0.001).
Conclusion Chemotherapy emerges as the only common prognostic factor shared by PSCCE patients in both China and the United States, establishing itself as a pivotal component within multidisciplinary treatment approaches. For limited-stage patients, it′s also crucial to acknowledge the significance of chemotherapy, emphasizing preference for combination regimens that incorporate chemotherapy. 


Key words: esophageal neoplasms, SEER database, prognosis